Compounds of Formula I:pharmaceutically acceptable salts thereof, enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof； or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of Formula I, or enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof； or a combination thereof, wherein the compound is double and/or triple agent or ligand for CYP2D6, 5-HT2A, and/or 5HT2C receptors, and/or acetylcholinesterase； and methods comprising co-administering a compound of Formula I and an N-Methyl-d-Aspartate (NMDA) receptor antagonist to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof. The compositions contain one of more ligands for CYP2D6, 5-HT2A, 5HT2C, and N-Methyl-d-Aspartate (NMDA) receptors, and acetylcholinesterase.
